A heterologous prime-boost strategy for immunization against Dengue virus combining the Tetra DIIIC subunit vaccine candidate with the TV005 live-attenuated tetravalent vaccine

References

1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW et al. The global distribution and burden of dengue. Nature 2013; 496:504–507 [View Article]
   [Google Scholar]
2. Gubler DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 2002; 10:100–103 [View Article]
   [Google Scholar]
3. Halstead SB. Dengue London: Imperial College Press; 2008
4. Halstead SB. Dengue. Lancet 2007; 370:1644–1652 [View Article]
   [Google Scholar]
5. Katzelnick LC, Harris E, Baric R, Coller B-A, Coloma J. Immune correlates of protection for dengue: state of the art and research agenda. Vaccine 2017; 35:4659–4669 [View Article]
   [Google Scholar]
6. Fahimi H, Mohammadipour M, Haddad Kashani H, Parvini F, Sadeghizadeh M. Dengue viruses and promising envelope protein domain III-based vaccines. Appl Microbiol Biotechnol 2018; 102:2977–2996 [View Article]
   [Google Scholar]
7. Russell PK, Halstead SB. Challenges to the design of clinical trials for live-attenuated tetravalent dengue vaccines. PLoS Negl Trop Dis 2016; 10:e0004854 [View Article]
   [Google Scholar]
8. Feinberg MB, Ahmed R. Advancing dengue vaccine development. Science 2017; 358:865–866 [View Article]
   [Google Scholar]
9. Durbin AP, Kirkpatrick BD, Pierce KK, Carmolli MP, Tibery CM et al. A 12-Month-Interval dosing study in adults indicates that a single dose of the National Institute of allergy and infectious diseases tetravalent dengue vaccine induces a robust neutralizing antibody response. J Infect Dis 2016; 214:832–835 [View Article]
   [Google Scholar]
10. Osorio JE, Wallace D, Stinchcomb DT. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone. Expert Rev Vaccines 2016; 15:497–508 [View Article]
    [Google Scholar]
11. Kirkpatrick BD, Durbin AP, Pierce KK, Carmolli MP, Tibery CM et al. Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, Flavivirus-Naive adults. J Infect Dis 2015; 212:702–710 [View Article]
    [Google Scholar]
12. Rupp R, Luckasen GJ, Kirstein JL, Osorio JE, Santangelo JD et al. Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: a phase 1B randomized study. Vaccine 2015; 33:6351–6359 [View Article]
    [Google Scholar]
13. Osorio JE, Velez ID, Thomson C, Lopez L, Jimenez A et al. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infect Dis 2014; 14:830–838 [View Article]
    [Google Scholar]
14. Osorio JE, Partidos CD, Wallace D, Stinchcomb DT. Development of a recombinant, chimeric tetravalent dengue vaccine candidate. Vaccine 2015; 33:7112–7120 [View Article]
    [Google Scholar]
15. Osorio JE, Huang CY-H, Kinney RM, Stinchcomb DT. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine 2011; 29:7251–7260 [View Article]
    [Google Scholar]
16. Yauch LE, Zellweger RM, Kotturi MF, Qutubuddin A, Sidney J et al. A protective role for dengue virus-specific CD8+ T cells. J Immunol 2009; 182:4865–4873 [View Article]
    [Google Scholar]
17. Zellweger RM, Miller R, Eddy WE, White LJ, Johnston RE et al. Role of humoral versus cellular responses induced by a protective dengue vaccine candidate. PLoS Pathog 2013; 9:e1003723 [View Article]
    [Google Scholar]
18. Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A 2013; 110:E2046–E2053 [View Article]
    [Google Scholar]
19. Weiskopf D, Sette A. T-cell immunity to infection with dengue virus in humans. Front Immunol 2014; 5:93 [View Article]
    [Google Scholar]
20. McArthur MA, A Promising ER. Single-dose, live attenuated tetravalent dengue vaccine candidate. J Infect Dis 2015
    [Google Scholar]
21. Kardani K, Bolhassani A, Shahbazi S. Prime-boost vaccine strategy against viral infections: mechanisms and benefits. Vaccine 2016; 34:413–423 [View Article]
    [Google Scholar]
22. Suzarte E, Marcos E, Gil L, Valdés I, Lazo L et al. Generation and characterization of potential dengue vaccine candidates based on domain III of the envelope protein and the capsid protein of the four serotypes of dengue virus. Arch Virol 2014; 159:1629–1640 [View Article]
    [Google Scholar]
23. Suzarte E, Gil L, Valdés I, Marcos E, Lazo L et al. A novel tetravalent formulation combining the four aggregated domain III-capsid proteins from dengue viruses induces a functional immune response in mice and monkeys. Int Immunol 2015; 27:367–379 [View Article]
    [Google Scholar]
24. Gil L, Lazo L, Valdés I, Suzarte E, Yen P et al. The tetravalent formulation of domain III-capsid proteins recalls memory B- and T-cell responses induced in monkeys by an experimental dengue virus infection. Clin Transl Immunology 2017; 6:e148 [View Article]
    [Google Scholar]
25. Lazo Vázquez L, Suzarte Portal E, Castro Velazco J, Yen P, Dung LT et al. Screening for immune response against dengue virus in Vietnamese non-human primates: implications for vaccine developers. Clin Transl Immunology 2017; 6:e135 [View Article]
    [Google Scholar]
26. Blaney JE, Matro JM, Murphy BR, Whitehead SS. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol 2005; 79:5516–5528 [View Article]
    [Google Scholar]
27. Kilgore KM, Murphy MK, Burton SL, Wetzel KS, Smith SA et al. Characterization and implementation of a diverse simian immunodeficiency virus SIVsm envelope panel in the assessment of neutralizing antibody breadth elicited in rhesus macaques by multimodal vaccines expressing the SIVmac239 envelope. J Virol 2015; 89:8130–8151 [View Article]
    [Google Scholar]
28. Hu X, Valentin A, Dayton F, Kulkarni V, Alicea C et al. DNA prime-boost vaccine regimen to increase breadth, Magnitude, and cytotoxicity of the cellular immune responses to subdominant Gag epitopes of simian immunodeficiency virus and HIV. J Immunol 2016; 197:3999–4013 [View Article]
    [Google Scholar]
29. Andersson A-MC, Holst PJ. Increased T cell breadth and antibody response elicited in prime-boost regimen by viral vector encoded homologous SIV Gag/Env in outbred cd1 mice. J Transl Med 2016; 14:343 [View Article]
    [Google Scholar]
30. Gil L, Marcos E, Izquierdo A, Lazo L, Valdés I et al. The protein DIIIC-2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV-2. Immunol Cell Biol 2015; 93:57–66 [View Article]
    [Google Scholar]
31. Valdés I, Bernardo L, Gil L, Pavón A, Lazo L et al. A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology 2009; 394:249–258 [View Article]
    [Google Scholar]
32. Weiskopf D, Angelo MA, Grifoni A, O'Rourke PH, Sidney J et al. HLA-DRB1 alleles are associated with different magnitudes of dengue virus-specific CD4⁺ T-cell responses. J Infect Dis 2016; 214:1117–1124 [View Article]
    [Google Scholar]
33. Gil L, Cobas K, Lazo L, Marcos E, Hernández L et al. A tetravalent formulation based on recombinant nucleocapsid-like particles from dengue viruses induces a functional immune response in mice and monkeys. J Immunol 2016; In Press:
    [Google Scholar]
34. Weiskopf D, Angelo MA, Bangs DJ, Sidney J, Paul S et al. The human CD8⁺ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes. J Virol 2015; 89:120–128 [View Article]
    [Google Scholar]
35. Grifoni A, Angelo MA, Lopez B, O'Rourke PH, Sidney J et al. Global assessment of dengue virus-specific CD4⁺ T cell responses in dengue-endemic areas. Front Immunol 2017; 8:1309 [View Article]
    [Google Scholar]
36. Whitehead SS. Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?. Expert Rev Vaccines 2016; 15:509–517 [View Article]
    [Google Scholar]
37. Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J Infect Dis 2013; 207:957–965 [View Article]
    [Google Scholar]
38. Kaufman BM, Summers PL, Dubois DR, Eckels KH. Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg 1987; 36:427–434 [View Article]
    [Google Scholar]
39. Valdés I, Hermida L, Martín J, Menéndez T, Gil L et al. Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis. Vaccine 2009; 27:995–1001 [View Article]
    [Google Scholar]
40. Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, Chanock RM, Whitehead SS, Murphy BR et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am J Trop Med Hyg 2001; 65:405–413 [View Article]
    [Google Scholar]